Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis

Akira S, Shigeo Akira, Mine K, Katsuya Mine, Kuwabara Y, Yoshimitsu Kuwabara, Takeshita T, Toshiyuki Takeshita
Medical science monitor : international medical journal of experimental and clinical research · 2009 · vol. 15(1) , pp. CR1–4 · PMID:19114964 · W2214895986
Observational OA: closed CC0 ⤵ 18 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Long-term, low-dose GnRH agonist therapy for adenomyosis effectively reduced pelvic pain and vasomotor symptoms while maintaining plasma estradiol within a therapeutic window and minimizing bone density loss.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: The usefulness of long-term, low-dose gonadotropin-releasing hormone agonist (GnRHa; buserelin acetate) therapy, so-called draw-back therapy, for the treatment of adenomyosis was investigated not. MATERIAL/METHODS: A retrospective observational study was conducted covering the period between January 2003 and March 2008. The subjects consisted of 12 patients with adenomyosis who underwent draw-back therapy for 2 years and had previously received GnRHa. GnRHa was initiated at 900 microg/day (6 nasal sprays/day). When the CA-125 level normalized, the GnRHa dosage was adjusted to 150-750 microg/day to achieve a plasma estradiol (E2) concentration of 20-50 pg/ml (i.e., the therapeutic window). Pain during withdrawal bleeding and chronic pelvic pain were assessed using a visual analogue scale. In addition, bone mineral density (BMD) of the lumbar vertebrae was measured using dual-energy X-ray absorptiometry. RESULTS: The mean GnRHa dose during draw-back therapy was 435 microg/day (2.9 nasal sprays/day). The mean E2 level during draw-back therapy was 36.3+/-14.3 pg/ml. The intensity of chronic pelvic pain was significantly lower during draw-back therapy than before draw-back therapy, and was nearly eliminated in many patients (4.8+/-1.2 vs. 0.6+/-0.7, respectively [p=0.000]). Compared to the severity of vasomotor symptoms during previous regular GnRHa therapy, the severity of vasomotor symptoms during draw-back therapy was significantly lower (3.8+/-0.7 vs 1.1+/-0.7, respectively [p=0.000]). The decrease in BMD during a 6-month course of treatment was 0.96+/-0.9%. CONCLUSIONS: GnRHa draw-back therapy allowed maintenance of plasma E2 levels within the therapeutic window. GnRHa can thus be administered for long periods of time while maintaining therapeutic effects on adenomyosis and suppressing adverse events.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosischronic_pelvic_pain

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Absorptiometry, Photon Absorptiometry, Photon Analysis of Variance Analysis of Variance Bone Density Bone Density Buserelin Buserelin CA-125 Antigen CA-125 Antigen CA-125 Antigen Dose-Response Relationship, Drug Dose-Response Relationship, Drug Endometriosis Endometriosis Estrogens Estrogens

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (17)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:06:07.402396+00:00
License: CC0 · commercial use OK